Nagendran Sukumar
President and Head of R&D at TSHA; Sr. VP & Chief Medical Officer at AveXis, Inc.
- Sold, on record
- $8.2M
- Dollars the filings state
- Form 4 sales
- 19
- Latest Jul 10, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- TSHATaysha Gene Therapies, Inc.President and Head of R&D
- AveXis, Inc.Sr. VP & Chief Medical Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- TSHA1.3M shares
- AveXis, Inc.21,361 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale AveXis, Inc.UnusualMar 1 2018
Sold 1,780 shares at $126.19 ($225k)
Nagendran Sukumar, Sr. VP & Chief Medical Officer
Sold 100% of holdings ($225k position)0 shares left1x usual sizeFiling
- 2 Form 4 sale TSHANo planAug 21 +2730 days
Sold 57,054 shares at $2.85 ($163k)
Nagendran Sukumar, President and Head of R&D
No 10b5-1 planSold 4.7% of holdings ($3.5M position)1.2M shares leftFirst sale on recordFiling
- 3 Form 4 sale TSHARoutineSep 10 +20 days
Sold 200,000 shares at $3.23 ($646k)
Nagendran Sukumar, President and Head of R&D
10b5-1 planSold 16.6% of holdings ($3.9M position)1M shares leftFiling
- 4 Form 4 sale TSHAUnusualDec 1 +82 days
Sold 370,172 shares at $4.58 ($1.7M)
Nagendran Sukumar, President and Head of R&D
No 10b5-1 planSold 26.9% of holdings ($6.3M position)1M shares leftFiling
- 5 Form 4 sale TSHARoutineJan 12 +42 days
Sold 200,000 shares at $4.71 ($942k)
Nagendran Sukumar, President and Head of R&D
10b5-1 planSold 16.6% of holdings ($5.7M position)1M shares left1x usual sizeFiling
- 6 Form 4 sale TSHANo planJan 26 +14 days
Sold 116,050 shares at $4.72 ($547k)
Nagendran Sukumar, President and Head of R&D
No 10b5-1 planSold 8.1% of holdings ($6.8M position)1.3M shares left0.6x usual sizeFiling
- 7 Form 4 sale TSHARoutineApr 10 +74 days
Sold 200,000 shares at $4.46 ($892k)
Nagendran Sukumar, President and Head of R&D
10b5-1 planSold 15% of holdings ($6M position)1.1M shares left1x usual sizeFiling
- 8 Form 4 sale TSHARoutineJul 10 +91 days
Sold 200,000 shares at $6.24 ($1.2M)
Nagendran Sukumar, President and Head of R&D
10b5-1 planSold 17.6% of holdings ($7.1M position)936,410 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (19)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | TSHA | President and Head of R&D | Form 4 sale | 200,000 | $1.2M | 17.6% | Routine | SEC |
| Apr 10, 2026 | TSHA | President and Head of R&D | Form 4 sale | 200,000 | $892k | 15.0% | Routine | SEC |
| Jan 26, 2026 | TSHA | President and Head of R&D | Form 4 sale | 116,050 | $547k | 8.1% | No plan | SEC |
| Jan 12, 2026 | TSHA | President and Head of R&D | Form 4 sale | 200,000 | $942k | 16.6% | Routine | SEC |
| Dec 1, 2025 | TSHA | President and Head of R&D | Form 4 sale | 370,172 | $1.7M | 26.9% | Unusual | SEC |
| Sep 10, 2025 | TSHA | President and Head of R&D | Form 4 sale | 200,000 | $646k | 16.6% | Routine | SEC |
| Aug 21, 2025 | TSHA | President and Head of R&D | Form 4 sale | 57,054 | $163k | 4.7% | No plan | SEC |
| Mar 1, 2018 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $225k | 100.0% | Unusual | SEC |
| Feb 1, 2018 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $210k | 100.0% | Unusual | SEC |
| Jan 2, 2018 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $195k | 100.0% | Unusual | SEC |
| Dec 1, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $169k | 100.0% | Unusual | SEC |
| Nov 1, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $180k | 100.0% | Unusual | SEC |
| Oct 2, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $173k | 100.0% | Unusual | SEC |
| Sep 1, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $166k | 100.0% | Unusual | SEC |
| Aug 1, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $163k | 100.0% | Unusual | SEC |
| Jul 3, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $146k | 100.0% | Unusual | SEC |
| Jun 1, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $126k | 100.0% | Unusual | SEC |
| May 1, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,780 | $145k | 100.0% | Unusual | SEC |
| Apr 3, 2017 | AveXis, Inc. | Sr. VP & Chief Medical Officer | Form 4 sale | 1,781 | $136k | 100.0% | Unusual | SEC |